This article is more than 5 years old. Information may no longer be current.
OSN’s top news of the week
Click Here to Manage Email Alerts
Here are five important articles from the past week you might have missed:
Europe approves first gene therapy for retinal dystrophy
On Nov. 23, the European Commission approved the first gene therapy for the treatment of inherited retinal disease related to a mutation of the RPE65 gene. Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and Lichtenstein. Read more.
AcuFocus receives FDA approval for IC-8 clinical study
AcuFocus received approval for an investigational device exemption from the FDA to conduct a clinical study of the IC-8, a small aperture monofocal IOL for patients with cataracts. Read more.
First patient enrolled in phase 3 MicroStat program
Eyenovia has enrolled the first patient in its phase 3 MicroStat program for pharmacologic mydriasis. Read more.
Micro-dose latanoprost effective in lowering IOP
A phase 2 study found micro-doses of latanoprost were consistent with standard drops in lowering IOP and were more likely to be successfully administered by subjects. Read more.
Golimumab reduced occurrence, disease activity of acute anterior uveitis in AS
The occurrence rate and disease activity of acute anterior uveitis in ankylosing spondylitis decreased significantly during treatment with golimumab, according to data published in the Journal of Rheumatology. Read more.